Commentary
Video
Adding to the Literature of KIF5A in ALS Pathogensis: Devesh Pant, PhD
Author(s):
The instructor in the department of cell biology at Emory University provided context on a presentation at MDA 2024 regarding mutations in Kif5a in familial forms of amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
"It’s kind of interesting and challenging to work on a gene which you can use to try to answer 4 different diseases, and hopefully, we can find some useful targets that can be used for as biomarkers, or even for therapeutics."
About 90% of amyotrophic lateral sclerosis (ALS) cases are sporadic, while the remaining 10% are familial. In recent years, there has been great advances in understanding the genetic makeup of these familial cases, with more than 40 associated genes now identified. In 2023, the field saw its first approval for a therapy (tofersen; Biogen) to specifically target patients with SOD1-mutated mediated ALS, one of the most common familial forms of the disease.
Although drug development has ramped up, patients with ALS lack validated biomarkers and therapeutically beneficial targets. Recently, loss and gain of function in KIF5A, a kinesin superfamily motor protein that transports various cargos in neurons, was suggested as a potential cause for certain forms of familial ALS. Research has shown that mutations in KIFs and dynein subunits often cause motor neuron diseases, such as ALS, Charcot-Marie-Tooth disease and spastic paraplegia.1
At the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held March 3-6, in Orlando, Florida, Devesh Pant, PhD, an instructor in the department of cell biology at Emory University, presented on the investigation of ALS caused by mutant KIF5A. Following his presentation, he sat down with NeurologyLive® to discuss the subject matter and the promise behind KIF5A. Specifically, he talked about how the field is advancing the understanding of the role of this protein and its involvement in various neuromuscular disorders, and the next steps in bringing it to drug development.
Click here for more coverage of MDA 2024.
